Maiwei Group's Hong Kong IPO has been approved, after three unsuccessful attempts to file with the Hong Kong Stock Exchange.

On January 24, the China Securities Regulatory Commission issued a notice on the registration of the overseas issuance and listing of Mirxes Holding Company Limited (Mirxes Group Holding Co., Ltd.). Mirxes Group plans to issue no more than 46,620,000 shares of ordinary shares for listing on the Hong Kong Stock Exchange. It is reported that the Company has submitted three IPO applications to the Hong Kong Stock Exchange on July 25, 2023, April 30, 2024, and November 4, 2024, respectively. The prospectus shows that Mirxes Group was established in 2014 and is a miRNA technology company originating from Singapore, focusing on the global promotion of disease screening and diagnosis solutions. As of October 31, 2024, the Company has one core product (i.e., GASTROClearTM), two other commercialized products (i.e., LungClearTM and FortitudeTM), and six candidate products in the preclinical stage. The Company's core product GASTROClearTM is a miRNA detection panel composed of 12 miRNA biomarkers for gastric cancer screening. GASTROClearTM was successfully commercialized after obtaining a Class C IVD certificate from the Health Sciences Authority of Singapore (HSA) in May 2019. According to Frost & Sullivan, Mirxes Group is a pioneer and leader in the development and commercialization of miRNA-based blood tests for early cancer detection and other diseases. The Company is one of the few companies globally that has received regulatory approval for its *IVD products in the molecular cancer screening industry, and it is also the first and only company globally to receive regulatory approval for its IVD products for molecular gastric cancer screening.